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Background: Some reports have suggested that nephron-sparing surgery (NSS) may
protect against cardiovascular events (CVe) when compared with radical nephrectomy
(RN). However, previous studies did not adjust the results for potential selection bias
secondary to baseline cardiovascular risk.
Objective: To test the effect of treatment type (NSS vs RN) on the risk of developing CVe
after accounting for individual cardiovascular risk.
Design, setting, and participants: A multi-institutional collaboration including 1331
patients with a clinical T1a–T1b N0 M0 renal mass and normal renal function before
surgery (defined as an estimated glomerular filtration rate 60 ml/min/1.73 m2).
Intervention: RN (n = 462, 34.7%) or NSS (n = 869, 65.3%) between 1987 and 2013.
Outcome measurement and statistical analyses: CVe was defined as onset during the
follow-up period of coronary artery disease, cardiomyopathy, hypertension, vasculo-
pathy, heart failure, dysrhythmias, or cerebrovascular disease not known before
surgery. Cox regression analyses were performed. To adjust for inherent baseline
differences among patients, we performed multivariate analyses adjusting for all
available characteristics depicting the overall and cardiovascular-specific profile of
the patients.
Results and limitations: When stratifying for treatment type, the proportion of patients
who experienced CVe at 1, 5, and 10 yr was 5.5%, 9.9%, and 20.2% for NSS patients
compared to 8.7%, 15.6%, and 25.9%, respectively, for RN patients ( p = 0.001). In
multivariate analyses, patients who underwent NSS showed a significantly lower risk
of developing CVe compared with their RN counterparts (hazard ratio 0.57, 95% confi-
0.96; p = 0.03) after accounting for clinical characteristics and
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Conclusions: The risk of CVe after renal surgery is not negligible. Patients treated with
NSS have roughly half the risk of developing CVe relative to their RN counterparts. After
accounting for clinical characteristics, comorbidities, and cardiovascular risk at diagno-
sis, NSS independently decreases the risk of CVe relative to RN.
Patient summary: The risk of having a cardiovascular event after renal surgery decreases
if a portion of the affected kidney is spared.
# 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.
E U R O P E A N U R O L O G Y 6 7 ( 2 0 1 5 ) 6 8 3 – 6 8 96841. Introduction
Although nephron-sparing surgery (NSS) is still under-
utilized as treatment for patients with renal cell carcino-
ma (RCC), especially in nonacademic hospitals [1,2], basic
research findings and clinical data have recently sug-
gested that NSS may decrease the probability of cardio-
vascular events (CVe) after renal surgery when compared
with radical nephrectomy (RN) [3,4]. Moreover, NSS offers
the additional benefits of greater preservation of renal
function and less overtreatment of benign tumors and
clinically indolent malignancies [5]. However, the appar-
ent benefit in performing NSS might have been the result
of unmeasured confounding selection biases, such as
clinical characteristics and, specifically, individual cardio-
vascular risk [6,7]. Indeed, the presence of hypertension,
diabetes, smoking habit, and impaired preoperative renal
function may affect decisions to select one surgical
approach over the other, and these factors need to be
considered to accurately define the potential benefit in
performing NSS. Similarly, the controversial prospective
results reported for the European Organization for
Research and Treatment of Cancer (EORTC) 30904 trial
showing no benefit of NSS in terms of survival might have
been affected by major biases, mainly involving poor
accrual and crossover between treatment arms [8].
The current multi-institutional study represents the first
attempt to test the effect of treatment type (NSS vs RN) on
the risk of CVe development after accounting for individual
preoperative cardiovascular risk besides clinical tumor and
patient characteristics.
2. Patients and methods
2.1. Study population
A multi-institutional collaboration among four European tertiary care
centers allowed retrospective collection of data for 1973 patients with
normal preoperative renal function (defined as estimated glomerular
filtration rate [eGFR] 60 ml/min/1.73 m2) who underwent surgical
treatment between 1987 and 2013 for a clinical T1a–T1b N0 M0 renal
mass. Among these, complete data and details regarding preoperative
cardiovascular profile and follow-up information were available for
1331 patients. Patients treated with NSS underwent open, laparoscopic,
and robot-assisted surgery in 605 (69.6%), 148 (17.0%), and 116 (13.3%)
cases, respectively.
2.2. Clinical and pathological evaluation
A dedicated genitourinary pathologist examined the surgical specimens at
each single tertiary care center. TNM stages were assigned according to the
2009 American Joint Committee on Cancer/Union Internationale Contre leCancer classification (AJCC/UICC) [9]. Cases before the introduction of the
most recent classification scheme were reclassified. Clinical tumor size
was based on preoperative imaging and was defined as the greatest tumor
diameter in centimeters. GFR was calculated according to the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) formula for
younger patients (<70 yr) [10] and the Berlin Initiative Study (BIS1)
formula for older patients [11].
2.3. Outcome
CVe was defined as onset during the follow-up period of new coronary
artery disease, cardiomyopathy, vasculopathy, hypertension, heart
failure, dysrhythmias, or cerebrovascular disease not known before
surgery and requiring hospitalization. Intraoperative or perioperative
onset of CVe (up to 2 wk after surgery) was not considered as an event.
The treating physician or cardiologist defined the CVe type. CVe was
assessed in the NSS and RN groups by scrutinizing subsequent hospital
admissions charts or during periodic follow-up visit or, alternatively, by
phone call if a patient was referred to another hospital after surgery.
Information regarding the total CVe number after surgery for every
patient was not available in all the centers, so the primary outcome was
defined as the onset of at least one new CVe.
2.4. Statistical analyses
Statistical analyses and reporting and interpretation of the results were
conducted according to recently published guidelines [12]. First, descrip-
tive statistics were used to categorize the baseline characteristics among
patients treated with either NSS or RN. The Kaplan-Meier method was
used to depict the rate of CVe over the time. Second, to test the hypothesis
that treatment type may affect the risk of CVe after surgery, univariate and
multivariate Cox regression analyses were performed. To adjust for
inherent baseline differences among patients, we included age, year of
surgery, preoperative and postoperative GFR, clinical tumor size, clinical
stage (cT1a vs cT1b), gender, symptoms (none vs local vs systemic),
hypertension (none vs controlled by medication vs not controlled by
medication), diabetes, baseline Charlson comorbidity index (CCI; 0 vs 1–2
vs 3), body mass index (BMI), and smoker status as covariates.
Postoperative GFR is strongly related to treatment type (NSS vs RN),
so the effect of postoperative renal function on CVe risk was also tested.
The relationship between postoperative GFR and the outcome of interest
is probably nonlinear, so the GFR effect on CVe was modeled using
restricted cubic splines with knots at the tertiles. The curve was
controlled for all confounders included in the above-mentioned
multivariate model and stratified according to the treatment delivered.
Confidence intervals (CIs; 95%) are presented.
Statistical tests were performed using SPSS version 20 (IBM Corp.,
Somers, NY, USA). All tests were two-sided with a significance level set at
p < 0.05.
3. Results
Table 1 shows the clinical, surgical, and pathologic char-
acteristics of the patients. Patients underwent RN (n = 462,
34.7%) or NSS (n = 869, 65.3%). The median follow-up period
Table 1 – Descriptive statistics for 1331 patients diagnosed with renal cell carcinoma stratified according to the type of treatment
Total (n = 1331) NSS (n = 869) RN (n = 462) p value
Clinical characteristics
Age at diagnosis (yr) 62 (53–70) 62 (53–70) 62 (54–70) 0.4a
Body mass index (kg/m2) 26.0 (23.8–28.0) 25.6 (23.6–28.0) 26.0 (24.0–28.0) 0.2a
Gender (%) 0.05b
Male 66.6 70.1 64.8
Female 33.4 29.9 35.2
Smoker (%) 14.7 16.2 22.9 0.002b
Hypertension (%) <0.001b
None 55.4 55.7 55.0
HT not controlled by medication 14.7 17.1 10.0
HT controlled by therapy 29.9 27.2 35.0
Diabetes (%) 11.1 11.9 9.5 0.2b
Creatinine at diagnosis (mg/dl) 0.89 (0.76–1.00) 0.88 (0.73–1.00) 0.90 (0.79–1.00) 0.08a
GFR (ml/min/1.73 m2)
At diagnosis 84 (70–96) 85 (70–98) 81 (70–93) 0.02a
At last follow-up 73 (58–87) 78 (64–93) 62 (52–76) <0.001a
Charlson comorbidity index (%) <0.001b
0 62.5 66.3 55.4
1–2 27.6 24.4 33.5
3 9.9 9.3 11.0
Symptoms at diagnosis (%) <0.001b
None 60.6 68.2 46.1
Local 32.3 27.0 42.2
Systemic 7.1 4.7 11.7
Clinical tumor size (cm) 3.7 (2.7–5.0) 3.0 (2.3–4.0) 5.0 (4.0–6.0) <0.001a
Clinical tumor stage (%) <0.001b
cT1a 60.0 75.9 30.1
cT1b 40.0 24.1 69.9
Surgical characteristics
Operating time (min) 140 (110–180) 135 (109–180) 150 (120–185) <0.001a
Ischemia time, NSS only (min) 15 (8–20) 15 (8–20) – –
NSS = nephron-sparing surgery; RN = radical nephrectomy GFR = glomerular filtration rate.
Data for continuous variables are presented as median (interquartile range).
a Independent t test.
b Chi-square test.
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mo). At 1, 5, and 10 yr, the proportion of patients who
experienced CVe was 7.1%, 12.6%, and 21.8%, respectively.
When stratifying for treatment type (NSS vs RN), the
proportion of patients who experienced a CVe was 5.5%
versus 8.7% at 1 yr, 9.9% versus 15.6% at 5 yr, and 20.2% versus
25.9% at 10 yr, respectively ( p = 0.001; Fig. 1).
According to univariate analysis, treatment type (NSS vs
RN) was strongly associated with CVe (hazard ratio [HR]
0.65, 95% confidence interval [CI] 0.49–0.87; p = 0.003).
Similarly, patient age, comorbidities, symptoms, diabetes,
hypertension, smoker status, and preoperative and postop-
erative GFR were associated with CVe risk during the
follow-up period (all p < 0.05).
In multivariate analyses (Table 2), patients who under-
went NSS showed a significantly lower risk of developing
CVe compared with their RN counterparts (HR 0.57, 95%CI
0.34–0.96; p = 0.03) after accounting for clinical character-
istics and cardiovascular profile. Figure 2 shows the
multivariate predicted probability of CVe according to
renal function after surgery and stratified for the type of
treatment. For NSS, the CVe risk remained stably low in
patients with normal function after surgery (GFR 60 ml/
min/1.73 m2). A higher CVe risk was observed in NSS
patients who developed any grade of CKD during the follow-
up period (GFR < 60 ml/min/1.73 m). Conversely, in RNcases, CVe risk was slightly increased even in patients with
normal renal function, reaching a plateau in patients who
developed severe CKD (<45 ml/min/1.73 m2).
4. Discussion
NSS is currently the standard of care for patients who are
candidates for surgery for a clinical T1 renal mass when
technically feasible [13–15]. It has been demonstrated that
NSS is equivalent to RN in terms of cancer control [8,
16–19]. Although conservative surgery may be more
challenging, especially for larger and more complex tumors
[20], NSS is associated with better functional outcomes
when compared to RN [21]. Finally, recent data have
suggested a potential benefit in terms of decreasing the risk
of subsequent CVe in patients treated with NSS in
comparison to RN. Specifically, three categories of evidence
suggesting an effect of NSS on cardiovascular risk are now
available. First, recent basic research findings demonstrate
that atherosclerotic lesions and collagen deposits are
significantly increased in mice treated with RN compared
with mice that underwent partial nephrectomy or sham
operations [4]. Second, it has been demonstrated that RN is
associated with lower postoperative GFR levels relative to
NSS (level 1b evidence) [22] and that the risk of CVe also
decreases directly with eGFR [23,24]. In addition, reduced
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Fig. 1 – Kaplan-Meier curve depicting the rate of cardiovascular events (CVe) stratified according to the type of surgery. CVe was defined as onset
during the follow-up period of coronary artery disease, cardiomyopathy, hypertension, heart failure, dysrhythmias, or cerebrovascular disease not
known before surgery. RN = radical nephrectomy; NSS = nephron-sparing surgery.
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cular risk factors (eg, increased levels of inflammatory
factors [25], high apolipoprotein levels, anemia [26], left
ventricular hypertrophy, increased arterial calcificationTable 2 – Multivariate Cox regression analyses predicting the onset
of cardiovascular events in the total patient cohort
HR (95% CI) p value
Type of treatment (NSS vs RN) 0.57 (0.34–0.96) 0.03
Preoperative characteristics
Preoperative GFR 0.99 (0.98–1.01) 0.5
Age 1.02 (0.99–1.05) 0.1
Gender (male vs female) 1.21 (0.74–1.98) 0.4
Year of surgery 1.15 (1.08–1.23) <0.001
Charlson comorbidity index 0.04
1–2 versus 0 1.51 (0.91–2.51) 0.1
3 versus 0 2.15 (1.11–4.17) 0.02
Symptoms at diagnosis <0.001
Local versus none 3.26 (1.98–5.34) <0.001
Systemic versus none 5.13 (2.73–9.64) <0.001
Clinical tumor size 0.91 (0.70–1.18) 0.5
Clinical stage (cT1b vs cT1a) 1.18 (0.52–2.63) 0.7
Cardiovascular profile
Diabetes 0.77 (0.38–1.58) 0.4
Postoperative GFR 0.99 (0.98–1.01) 0.4
Hypertension 0.007






Body mass index 1.04 (0.98–1.10) 0.2
Smoker status 1.06 (0.80–1.40) 0.7
NSS = nephron-sparing surgery; RN = radical nephrectomy; GFR = glomerular
filtration rate; HR = hazard ratio; CI = confidence interval; HT = hypertension.[27,28], endothelial dysfunction, and arterial stiffness
[29,30]). Third, population-based studies have revealed a
greater number of CVe in patients treated with RN in
comparison to NSS [3,31]. For instance, Huang et al [3]
analyzed the Surveillance, Epidemiology, and End Results
(SEER)-Medicare cancer registry and collected data for
2991 patients treated with NSS (19%) or RN (81%) between
1995 and 2002. For a mean follow-up period of 43 mo they
reported a CVe rate of 20% after surgery, similar to the
current study, with a 1.4-fold greater number of events after
RN ( p < 0.05). Besides the relatively low number of NSS
patients and the short follow-up period, unfortunately the
authors could not adjust their results for tumor size, smoker
status, and BMI, all possible confounders for patient selection
and potential CVe predictors. Moreover, the majority of
published studies have relied on US patient cohorts. Few data
are available regarding the effect of NSS on CVe risk in
European patients, who typically show a lower risk of
cardiovascular death relative to their US counterparts
[32]. Specifically, differences in patient lifestyles and diets
and a potential dissimilar baseline genetic environment may
play a role in evaluation of the effect of NSS on CVe risk.
Conversely, other reports did not confirm a difference
in the rate of CVe after surgery. Miller et al [33] performed a
retrospective cohort study based on linked SEER-Medicare
data. The authors identified 10 886 patients who under-
went NSS or RN between 1991 and 2002 and calculated
propensity scores to balance the treatment cohorts with
respect to measured patient and disease characteristics.
The likelihood of adverse cardiovascular outcomes did not
differ by treatment [33]. Recently, Shuch et al [34] noted a
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Fig. 2 – Multivariate predicted probability of a cardiovascular event (CVe) according to renal function after surgery. Green line, nephron-sparing
surgery; orange line, radical nephrectomy; gray lines, 95% confidence intervals. The curve is controlled for all confounders included in the full
multivariate model (age, year of surgery, preoperative clinical tumor size, clinical stage, gender, symptoms, hypertension, diabetes, baseline Charlson
comorbidity index, body mass index, and smoker status). eGFR = estimated glomerular filtration rate.
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RN compared to noncancer controls ( p < 0.0001). Unfortu-
nately, they did not directly compare the two treatments to
verify a difference in the risk of cardiovascular events
associated with one type of treatment for RCC [34].
For the first time, we performed an adjusted comparison
between patients with T1 renal masses treated with either
NSS or RN after accounting for the individual cardiovascular
profile before surgery, as well as clinical and tumor
characteristics. We demonstrated that the risk of CVe after
renal surgery is not negligible and that NSS independently
decreases the risk of CVe relative to RN, even after
accounting for potential confounders and selection biases
that were not considered in previous studies. The impor-
tance of these findings is even greater in the context of novel
strategies such as active surveillance, which have been
gaining in popularity for treatment of small masses,
especially for older and sicker patients.
Finally, we confirmed the importance of postoperative
GFR levels for the risk of developing CVe after surgery.
Preservation of renal function is one of the most important
aims when NSS is pursued. Moreover, a significant part of the
CVe risk benefit secondary to NSS can probably be attributed
to the protective effect of NSS on postoperative GFR. In the
current study, interesting data emerged when the effect of
postoperative GFR on CVe risk was stratified for treatment
type (NSS vs RN) and analyzed in nonlinear multivariate
modeling (Fig. 2). Specifically, after accounting for all the
available baseline and cardiovascular confounders, CVe risk
remained stably low in NSS patients with normal renalfunction after surgery (GFR 60 ml/min/1.73 m2). Higher
CVe risk was observed in patients treated with NSS who
developed any grade of CKD (GFR < 60 ml/min/1.73 m2)
during the follow-up period. Conversely, CVe risk was
slightly increased in RN patients with normal renal function,
reaching a plateau in those who developed severe CKD
(<45 ml/min/1.73 m2). These results may be because NSS
protects renal function against surgically induced CKD and
that the higher CVe risk is probably subsequent to the
development of CKD secondary to a medical condition,
independent of previous surgery (eg, new onset of diabetes or
other metabolic syndromes). Conversely, in RN patients we
probably observed a combination of both the conditions
(surgically induced CKD and possible secondary medical
CKD) and a gradual increase in CVe risk secondary to a
decrease in postoperative GFR. Finally, at very low GFR levels
the CVe risk was higher for NSS than for RN patients. This is
probably because in NSS patients with T1 cancers, end-stage
CKD is secondary to medical conditions in the majority of
cases since nephrons are largely spared during surgery.
Conversely, in RN patients the surgically induced loss of
nephrons accounts for a substantial proportion of the
pathogenesis of end-stage CKD and, as recently demonstrat-
ed by Lane and colleagues [35], surgically induced CKD is
usually associated with a lower risk of clinical progression
than medical CKD.
Our study provides a fairer comparison of CVe risk
between NSS and RN for the first time because we took
into account many confounders that were not included
in previous reports (eg, hypertension not controlled by
E U R O P E A N U R O L O G Y 6 7 ( 2 0 1 5 ) 6 8 3 – 6 8 9688medication, diabetes, smoker status, BMI). Besides its
strengths, the retrospective nature of the study is certainly
a limitation. Specifically, as was the case for the majority of
the data available on the topic, the results could not be
adjusted for other potential confounders, such as hyperlip-
idemia, exercise activity, and alcohol use, or for possible
differences in terms of follow-up assessment between the
two cohorts.
5. Conclusions
The risk of CVe after renal surgery is not negligible. Patients
treated with NSS have roughly half the risk of developing
CVe relative to their RN counterparts. NSS independently
decreases the risk of CVe relative to RN, even after
accounting for clinical characteristics, comorbidities, and
cardiovascular risk at diagnosis.
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